breast cancer

[npj Breast Cancer] Scientists showed that reverting the high LIP/LAP ratios in TNBC cell lines into low LIP/LAP ratios by overexpression of LAP reduced migration and matrix invasion of these TNBC cells.

[npj Breast Cancer] The authors evaluated the transcriptome of an extended series of inflammatory breast cancer (IBC) preclinical models and performed a comparative analysis with patient samples to determine the extent to which the current models recapitulate the molecular characteristics of IBC observed clinically.

[Cell Reports] Investigators analyzed lineage-dependent gene expression in human breast tumors to identify differences in metabolic gene expression that may limit pathway redundancy and create therapeutic vulnerabilities.

[Molecular Cancer Research] The authors demonstrated that MUC1-C drove global changes in chromatin architecture in the dedifferentiation of CRPC and triple-negative breast cancer cells.

[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.

[Veru, Inc.] Veru, Inc. announced that the US FDA has granted Fast Track designation to the Phase III registration program for the investigation of enobosarm for the treatment of androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) metastatic breast cancer patients.